INTRODUCTION
============

Aspirin-exacerbated respiratory disease (AERD), is a clinical syndrome with inflammatory responses in both the upper and lower respiratory tracts ([@B1]). It is characterized by chronic rhinosinusitis with nasal polyposis which is followed by asthma and hypersensitivity to aspirin ([@B2]). Aspirin-induced bronchospasm in asthma patients are mediated by mast cell and eosinophilic inflammation which is already ongoing before the first aspirin ingestion ([@B2], [@B3]). The mechanisms for pathogenesis of AERD are not completely explained, however, it has been suggested that over-production of cysteinyl leukotriene (CysLT) and its receptor on inflammatory cells occurs in the respiratory tract of AERD patients ([@B4]).

The transmembrane protein encoded by *discoidin*, *CUB* and *LCCL domain-containing protein 2* (*DCBLD2*) gene, also abbreviated as *CLCP1* or *ESDN*, is regarded as a contributor for regulation of cell proliferation. Our previous genome-wide and follow-up studies showed nominal associations between *DCBLD2* polymorphisms and AERD ([@B5]). Despite little information on the function of *DCBLD2*, this gene has also been elucidated to be up-regulated in the development and metastasis of lung cancers ([@B6]). In addition, the transcription factor TFAP2A induces an inhibitory effect on *DCBLD2* transcription ([@B7]). The TFAP2A, an important transcription factor, is a component of activator protein-2 (AP-2) that regulates IL-8 expression in human lung fibroblasts and epithelial cells ([@B8]). On the other hand, previous studies have also proposed that the up-regulation of *DCBLD2* could be involved in pathways related to immune and injury-mediated remodeling ([@B9], [@B10]). In addition, *neuropilin-1*, whose domains are structurally similar with *DCBLD2* domain proteins and has been identified as an isoform of a specific vascular endothelial growth factor receptor in human airway epithelial cells, showed a higher expression in patients who have chronic rhinosinusitis and/or nasal polyposis ([@B9], [@B11]).

Based on the possible relations of *DCBLD2* to airway remodeling, we investigate further the associations of *DCBLD2* single nucleotide polymorphisms (SNPs) with the fall rates of forced expiratory volume by aspirin provocation as well as AERD development under various genetic models.

MATERIALS AND METHODS
=====================

Study subjects
--------------

Asthmatic subjects were recruited from the Asthma Genome Research Center comprising hospitals of Soonchunhyang University in Seoul and Bucheon, Chungnam National University and Chungbuk National University in Korea. Patients met the definition of asthma based on the Global Initiative for Asthma guidelines 2010 (<http://www.ginasthma.org/guidelines-gina-report-global-strategy-for-asthma.html>). All subjects had a history of dyspnea and wheezing during the past year plus one of the following: 1) \> 15% increase in forced expiratory volume in one second (FEV~1~) or \> 12% increase plus 200 mL following inhalation of a short-acting bronchodilator, 2) \< 10 mg/mL PC~20~ methacholine, or 3) \> 20% increase in FEV~1~ following 2 weeks of treatment with inhaled steroids and long-acting bronchodilators. Twenty-four common inhalant allergens (e.g., dust mites, cat fur, dog fur, cockroaches, grasses, trees, ragweed pollen; Bencard Co. Ltd., Brentford, UK) were used in a skin-prick test. Total IgE was measured by the CAP system (Pharmacia Diagnostics, Uppsala, Sweden). Atopy was defined as a wheal reaction equal to or greater than histamine or 3 mm in diameter.

The oral aspirin provocation test was performed with slight modifications in increasing doses of aspirin ([@B12]), following the guideline of EAACI/GA2LEN ([@B13]). Briefly, the patient having history of aspirin hypersensitivity was given 30 mg and those having no history started 100 mg of aspirin orally. Symptoms, external signs (urticaria and angioedema), blood pressure and FEV~1~ were documented every 30 min for a period of 2 hr. In the absence of any symptoms or signs suggestive of adverse reaction after 2 hr, 60 mg or 100 mg of aspirin was administered and the same measurements were repeated every 1 hr, with doses of 450 mg until the patient developed a reaction. If no reaction occurred 5 hr after the final dose, the test was deemed negative. Changes in the FEV~1~ were followed for 5 hr after the final aspirin dose. Aspirin-induced bronchospasm, reflected by the rate (%) of decline in FEV~1~, was calculated as the pre challenge FEV~1~ minus the post challenge FEV~1~ divided by the pre-challenge FEV~1~. Subjects were categorized into two groups based on OAC reactions: ≥ 20% decrease in FEV~1~ or a 15%-19% decrease in FEV~1~ with naso-ocular reactions as AERD patients group, whereas a \< 15% decrease in FEV~1~ without naso-ocular reactions as ATA controls group.

SNP selection and genotyping
----------------------------

We selected common SNPs based on the frequencies in Asian population from the International HapMap Project database (<http://hapmap.ncbi.nlm.gov/index.html.en>). The selected 12 SNPs were genotyped in a total of 592 asthmatic subjects composed of 163 AERD and 429 ATA subjects. Genotyping was carried out using TaqMan assay in the ABI prism 7900HT sequence detection system (Applied Biosystems, Carlsbad, California, USA) with the assessment of data quality by duplicate DNAs (n = 10). Genotype data were obtained using the ABI-PRISM sequence detection system (SDS) software version 2.3. SNPs that did not match the following standards were excluded from the study: 1) a minimum call rate of 95%; 2) no duplicate error; and 3) *P* values of Hardy-Weinberg Equilibrium more than 0.05. All the 12 SNPs of *DCBLD2* were successfully genotyped.

Statistics
----------

The association of SNPs and haplotypes of *DCBLD2* with AERD was carried out with logistic analyses controlling for age, sex, smoking status, atopy and body mass index (BMI) as covariates using the Statistical Analysis System (SAS). The FEV~1~ change induced by aspirin provocation which was considered as a continuous variable was subjected to a simple linear regression analysis, and the differences in the values among the genotypes or haplotypes were examined using a linear regression model that controlled for age, sex, atopy and smoking status as covariates. For linkage disequilibrium (LD), we examined Lewontin\'s D\' (\|D\'\|) and the LD coefficient *r*^2^ between all pairs of biallelic loci using the Haploview v4.1 software downloaded from the Broad Institute (<http://www.broadinstitute.org/mpg/haploview>) ([@B14]). Haplotypes were first estimated using PHASE software ([@B15]), and then computed by logistic analyses using SAS.

Ethics statement
----------------

The institutional review board approved the protocol (SCHBC_IRB_05_02), and all subjects provided informed consent.

RESULTS
=======

Characteristics of study subjects
---------------------------------

The clinical profiles of the study subjects are summarized in [Table 1](#T1){ref-type="table"}. All of the subjects were asthma patients and were divided into two groups, AERD patients and ATA control groups, according to degree of aspirin sensitivity. Overall, a decrease in FEV~1~ of -15% to 68% induced by aspirin provocation was observed. The percentage of decrease in FEV1 by aspirin provocation in AERD patients (24.6%) were significantly higher compared to ATA controls (3.5%; *P* \< 0.001). The values of predicted FEV~1~ %, PC~20~ methacholine and body mass index in AERD patients were significantly lower than those of ATA controls (*P* = 0.009, 0.02 and 0. 001, respectively). In addition, the mean age of a first medical examination in AERD was significantly lower than ATA (*P* = 0.001). Percentage of smoking status in AERD patients was also lower compared to ATA controls (*P* = 0.02).

Genotyping and haplotypes of *DCBLD2* polymorphisms
---------------------------------------------------

We selected 12 common polymorphisms of *DCBLD2*, six in exon regions and six in introns, based on the frequencies on Asian population from the International HapMap Project ([Table 2](#T2){ref-type="table"}, [Fig. 1](#F1){ref-type="fig"}). The minor allele frequencies (MAFs) of these 12 SNPs in the Korean asthmatics (n = 592) are shown in [Table 2](#T2){ref-type="table"}. The genotype distributions of all loci are in Hardy-Weinberg equilibrium ([Table 2](#T2){ref-type="table"}). The linkage disequilibrium coefficients (\|D\'\|) among the SNPs were calculated for all of the study subjects ([Fig. 1](#F1){ref-type="fig"}). Complete LDs were observed between two SNPs; *rs7615856* and *rs828621* (*r*^2^ = 1). Twelve haplotypes were constructed and five of them with frequencies over 0.05 (*DCBLD-ht1* to *DCBLD-ht5*) were included in the association analysis ([Fig. 1](#F1){ref-type="fig"}).

Associations of *DCBLD2* polymorphisms with FEV~1~ decline and AERD development
-------------------------------------------------------------------------------

Initially, this study investigated the associations between genotypes or haplotypes and the percentage of FEV~1~ decline following aspirin challenge using multiple linear regression analysis ([Table 3](#T3){ref-type="table"}). Interestingly, nine SNPs (*rs2439224*, *rs1371687*, *rs7615856*, *rs828621*, *rs828618*, *rs828616*, *rs16840208*, *rs17270986* and *rs8833*) were significantly associated with the percentage FEV~1~ decline induced by aspirin challenge in the asthmatics (*P* \< 0.05, [Table 3](#T3){ref-type="table"}). Furthermore, among the significantly associated SNPs, a non-synonymous SNP *rs16840208* (*D723N* or *Asp723Asn*) was found to induce a strong genetic effect (*P* = 0.02 under co-dominant; *P* = 0.009 in dominant model). In the haplotype analysis, *DCBLD2-ht1* and *DCBLD2-ht4* were also associated with the percentage FEV~1~ decline induced by aspirin challenge in the asthmatics (*P* = 0.009 for *DCBLD2-ht4* under dominant model to *P* = 0.02 for *DCBLD2-ht1* and *DCBLD2-ht4* under co-dominant, [Table 3](#T3){ref-type="table"}).

Furthermore, results from regression analysis comparing AERD and ATA groups revealed that nine SNPs (*P* = 0.001 for *rs828618* under dominant model to *P* = 0.05 for *rs2439224*, *rs828618*, *rs17270986* under co-dominant) and two haplotypes (*P* = 0.001 for *DCBLD2-ht1* under dominant model to *P* = 0.05 for *DCBLD2-ht1* under dominant; *P* = 0.03 for *DCBLD2-ht2* under recessive) were significantly associated with the percentage FEV~1~ decline induced by aspirin challenge in AERD patients ([Supplementary Table 1](#S1){ref-type="supplementary-material"}). In contrast, findings from regression analysis of ATA group showed no significant association between *DCBLD2* SNPs and FEV~1~ decline induced by aspirin provocation, except for *DCBLD2-ht1* haplotype (*P* = 0.02 in recessive model, [Supplementary Table 1](#S1){ref-type="supplementary-material"}).

In further association analysis between *DCBLD2* SNPs/haplotypes and the risk of AERD using multiple logistic models, two SNPs (*rs828618* and *rs828616*; *P* = 0.05 and *P* = 0.04, respectively) and one haplotype (*DCBLD2-ht1*; *P* = 0.05) showed nominal signals with the risk of AERD ([Table 4](#T4){ref-type="table"}).

DISCUSSION
==========

To our knowledge, this study is the first to investigate the association between *DCBLD2* and AERD. In this study, data from logistic and linear regression analyses showed significant associations of *DCBLD2* polymorphisms with FEV~1~ decline by aspirin provocation (*P* = 0.009 for *rs16840208* under dominant model to *P* = 0.04 for *rs7615856*, *rs828621* and *rs8833* under co-dominant, [Table 3](#T3){ref-type="table"}) and nominal signals to AERD development (*P* = 0.04 for *rs828616* to *P* = 0.05 for *rs828618* under co-dominant model, [Table 4](#T4){ref-type="table"}). Furthermore, the strength of association with the fall rate of FEV~1~ by aspirin provocation was increased in the AERD subgroup (*P* = 0.001 for *rs828618* under dominant model to *P* = 0.05 for *rs2439224*, *rs828618*, *rs17270986* under co-dominant, [Supplementary Table 1](#S1){ref-type="supplementary-material"}) compared to ATA (*P* \> 0.05), suggesting that genetic variations of *DCBLD2* may affect decline of FEV~1~ by aspirin provocation in AERD patients.

Recently, a significant up-regulation of *DCBLD2*, previously identified as *CLCP1*, has been elucidated in the metastasis of lung cancer cell line ([@B6]), suggesting that *DCBLD2* potentially plays a role in lung-related functions. In addition, *DCBLD2*, also known as ESDN, is a key factor in the modulation of vascular smooth muscle cell (VSMC) growth and regulation of VSMC proliferation processes that are involved in vascular remodeling. DCBLD2 is up-regulated in remodeling arteries, and its down-regulation by RNA interference (RNAi) has been found to significantly enhance VSMC DNA synthesis and migration through induction of platelet-derived growth factor (PDGF), a prototypic growth factor for VSMCs ([@B10], [@B16]).

The transcription factor TFAP2A, a member of the AP-2 family, plays an important role in regulation of *DCBLD2* transcription. It has been shown that TFAP2A binding to *DCBLD2* promoter region induces a decrease in promoter activity measured by luciferase assay in this gene. Conversely, mutations in TFAP2A binding site in *DCBLD2* promoter lead to the increase in transcription activity ([@B7]). AP-2 is a regulator for IL-8 production that is associated with the destructive pulmonary inflammation and the recruitment of neutrophils. Deletion of AP-2 binding site in the upstream region of *IL-8* promoter significantly decreased *IL-8* transcription activity ([@B8]), suggesting that DCBLD2 might be related to the production of interleukins in human pulmonary diseases through interaction with AP-2. This possibility is supported by the facts that discodin domain affects immune responses in the involvement of interleukins ([@B17], [@B18]).

Although the functional properties of DCBLD2 in tumor development and vascular remodeling have been reported, to date no previous study has proposed the functional or genetic effects of *DCBLD2* on asthma and aspirin-induced hypersensitivity. However, neuropilin-1, which is structurally similar to DCBLD2 ([@B19]) has been found to be related to the suppressor function of CD4^+^CD25^+^ T cells in airway inflammation and hyper-responsiveness ([@B20]). In addition, neuropilin-1 is associated with the development of nasal polyposis, one of the symptoms of AERD. Distribution of neuropilin-1, as a co-receptor of vascular endothelial growth factor (VEGF), was shown to be 7-fold higher in nasal lavage from patients with polyposis than control subjects. Moreover, blockade of VEGF, which is suppressed by neuropilin-1, results in increased apoptosis and inhibition of autocrine epithelial VGEF production ([@B11]). Therefore, with the structural similarity to neuropilin-1, there is a possibility DCBLD2 may play a similar role in aspirin sensitivity to asthma.

The bronchoalveolar lavage (BAL) in asthma has been implicated in asparagine levels. The BAL fluid from asthmatic patients showed higher level of asparagine (Asn, N) than from normal controls ([@B21]). Other studies have reported that a polymorphism in the human *neuropeptide S receptor* (*NPSR*) which produces an amino acid substitution from Asn to isoleusine (Ile) (*Asn107Ile*) is associated with susceptibility to asthma. The *Asn107Ile* polymorphism of *NPSR* was found to be highly expressed in human asthmatic airway tissue ([@B22], [@B23]). In the present study, *rs16840208* (*Asp723Asn*) is significantly associated with FEV~1~ decline by aspirin provocation (*P* = 0.02 under co-dominant and 0.009 under dominant model), suggesting that the amino acid change from aspartic acid (Asp) to asparagine of *rs16840208* may be a genetic factor affecting the risk of pulmonary diseases including asthma.

Among the SNPs associated with FEV~1~ decline by aspirin provocation and/or AERD, 5 SNPs (*rs2439224*, *rs1371687*, *rs7615856*, *rs828621*, and *rs828618*) were located in intronic region of *DCBLD2*. Despite difficulty in assessing the functions of SNPs that are not positioned at the exon and promoter regions, previous studies have suggested that intronic SNPs may play important roles in gene transcription rate and abnormal splicing events such as exon skipping, activation of cryptic splice sites and production of alternatively spliced isoforms in human disease phenotypes ([@B24], [@B25]). Furthermore, it has also been reported that intronic SNPs in *solute carrier family 6*, *member 7* (*SLC6A7*) ([@B26]), *solute carrier family 6*, *member 12* (*SLC6A12*) ([@B27]), *kinesin family number 3A* (*KIF3A*) ([@B28]), *calcium channel*, *voltage-dependent*, *gamma subunit 6* (*CACNG6*) ([@B29]) and *fibrous sheath interacting protein 1* (*FSIP1*) ([@B30]) are associated with asthma and/or decline in FEV~1~ by aspirin challenge.

In summary, findings from this study provide evidences that genetic polymorphisms of *DCBLD2* including a non-synonymous *rs16840208* (*Asp723Asn*) might induce decline in FEV~1~ by aspirin ingestion in Korean asthma patients. Furthermore, considering that 5-lipoxygenase, whose pathway is one of the central mechanisms to produce CysLTs from arachidonic acid ([@B31]), plays a role in VSMC that is modulated by DCBLD2 ([@B10], [@B32]), these findings suggest that genetic variants of *DCBLD2* could provide a new strategy for the control of aspirin intolerance.
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Supplementary Table 1

![Gene maps and haplotypes of *DCBLD2*. (**A**) Polymorphisms of *DCBLD2* investigated in this study. Coding exons are marked by shaded blocks; 5\'- and 3\'-untranslated region (UTR) by white blocks. Two SNPs (*rs7615856* and *rs828621*) are in complete LD (*r*^2^ = 1). (**B**) Haplotypes of *DCBLD2* in the Korean population. Only those with frequencies over 0.05 are analyzed for associations. (**C**) LD blocks and correlation coefficients among *DCBLD2* polymorphisms.](jkms-27-343-g001){#F1}
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Clinical profiles of study subjects
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Clinical profile of AERD was compared to ATA controls. AERD, aspirin-exacerbated respiratory disease; ATA, aspirin-tolerant asthma.
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Single nucleotide polymorphisms and minor allele frequencies of human *DCBLD2* in Korean subjects
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^\*^*P* values of deviation from Hardy-Weinberg Equilibrium (HWE) in Korean population. MAF, minor allele frequency.
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Association of SNPs and haplotypes of *DCBLD2* with FEV~1~ decline by aspirin provocation in asthmatics
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Genotype distribution of each SNP is presented as the number of subjects (percentage of FEV~1~ decline by aspirin provocation, mean ± SE). *P* values for linear regression analysis controlling age, sex, smoking status and atopy as covariates. C/C, Major homozygote; C/R, Heterozygote; R/R, Minor homozygote.

###### 

Analyses of association of *DCBLD2* polymorphisms with risk of AERD
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Logistic analyses controlling for age, sex, smoking status, atopy and body mass index (BMI) as covariates are performed using the Statistical Analysis System (SAS). OR (95% CI) and *P* values of co-dominant model are also reported in the supporting information of our previous report (Kim et al. 2010b). MAF, minor allele frequency; OR, odds ratio; CI, confidence interval.
